Sanofi (Ablynx)

Technologiepark 21

9052 Zwijnaarde


Sanofi (Ablynx)

Foundation date



#Biotechnology - Therapeutics


Therapeutic areas

Sanofi R&D Belgium based in Ghent is as an end-to-end research and early development Center of Excellence and active in the discovery of NANOBODY® molecules, through the development of drugs up to their clinical proof-of-concept.

NANOBODY® molecules are proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. NANOBODY® technology is the next generation of antibody-derived biologics and have great potential. They are being developed for the treatment of a range of serious and life-threatening human diseases including hematology, inflammation, immune-oncology, oncology and rare diseases.

Latest news

  • Researchers unravel complexities of Alzheimer’s disease in protein fragments and plaque diversity

    10 hours ago

  • New software from UHasselt and ZEISS shows in sharp detail how biomolecules move in cells.

    1 day ago

  • Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024

    1 day ago